MacroGenics (MGNX) AI Stock Analysis

• Market Cap: $92.74M
• Dividend Yield: N/A
• Average Volume (3M): 1.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.06
• Revenue Growth: 255.31%
• EPS Growth: -141.39%
• Country: US
• Employees: 341
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.65
• Shares Outstanding: 63,090,324
• 10 Day Avg. Volume: 1,600,120
• 30 Day Avg. Volume: 1,918,029
• PEG Ratio: 0.09
• Price to Book (P/B): 2.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.55
• Enterprise Value/Market Cap: 4.61
• Enterprise Value/Revenue: 0.88
• Enterprise Value/Gross Profit: 3.12
• Enterprise Value/Ebitda: -1.33
• 1Y Price Target: $4.10
• Price Target Upside: 159.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 49 Neutral
• Price Target: $1.50 ▼(-5.06%Downside)

MacroGenics' overall stock score reflects financial struggles, particularly in profitability and liquidity, partially offset by a positive corporate event that strengthens the company's cash position. The technical analysis indicates potential short-term stability, but fundamental valuation remains weak.

Positive Factors

Financial Stability

MGNX ended with $154.1M in cash and equivalents, providing an expected runway into the second half of 2026.

Pipeline Progress

MGNX continues to make progress across its broader pipeline, including the initiation of the Phase II LINNET study and the upcoming clinical update from the Phase II LORIKEET study.

Resource Allocation

The discontinuation of vobra duo is viewed positively as it allows the company to reallocate resources to programs with higher probability of success, including the second B7-H3 ADC program, MGC026.

Negative Factors

Clinical Risks

Risks include clinical setbacks with MGC026, lorigerlimab, MGC028, and MGC030, competitive landscape risks, partnership risks, and possible long-term dilution risk.

Financial Performance

MacroGenics reported a full-year 2024 net loss of $1.07 per share, slightly wider than the previous forecast of a net loss of $0.95 per share.

Price Target

The 12-month price target has been lowered to $2 per share from the prior $4 per share.

MacroGenics Business Overview & Revenue Model

Company Description

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company operates primarily in the biotechnology and pharmaceutical sectors, leveraging its proprietary DART and TRIDENT platforms to create multi-specific antibodies that engage the immune system to eradicate cancer cells. MacroGenics' pipeline includes several product candidates in various stages of clinical trials, targeting a range of cancers, with an emphasis on addressing unmet medical needs.

How the Company Makes Money

MacroGenics generates revenue through a combination of product sales, collaborative agreements, and licensing arrangements. The company earns revenue from its strategic partnerships with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties based on the successful development and commercialization of its therapeutic candidates. Additionally, MacroGenics may receive government grants and funding for specific research initiatives. The company's revenue is heavily reliant on the progress and commercialization of its pipeline products, as well as the success of its collaborative partnerships in advancing those products to market.

MacroGenics Financial Statement Overview

Summary

MacroGenics exhibits revenue growth but faces ongoing profitability challenges, with negative EBIT and net income. The balance sheet is stable with manageable debt, yet cash flow remains a concern due to negative free cash flow.

Income Statement

MacroGenics shows a mixed performance in terms of revenue and profitability. The TTM (Trailing-Twelve-Months) revenue is up from the previous year, indicating growth, but the company continues to report negative EBIT and net income, signaling ongoing operational challenges. Gross profit margins are strong, but net profit margins remain negative, reflecting the high costs affecting overall profitability.

Balance Sheet

The balance sheet of MacroGenics highlights a moderate financial position. The debt-to-equity ratio is relatively low, suggesting manageable leverage levels. However, the company's return on equity is negative due to consecutive net losses. The equity ratio indicates a fair portion of the assets are financed by equity, providing some stability.

Cash Flow

Cash flow analysis reveals challenges in generating positive cash flows. The company reports negative free cash flow in the TTM, although there is a slight improvement in operating cash flow. The free cash flow to net income ratio remains negative, indicating difficulties in turning net losses into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	152.43M	148.34M	57.19M	151.94M	75.64M	97.76M
Gross Profit	136.84M	136.04M	48.97M	144.56M	72.99M	-95.44M
EBITDA	-47.33M	-57.37M	2.02M	-107.89M	-190.86M	-117.78M
Net Income	-55.81M	-66.97M	-9.06M	-120.02M	-190.86M	-117.78M
Balance Sheet
Total Assets	224.56M	261.65M	298.42M	280.47M	335.25M	378.74M
Cash, Cash Equivalents and Short-Term Investments	154.14M	201.67M	229.81M	154.35M	243.62M	272.53M
Total Debt	37.47M	37.46M	33.97M	34.83M	25.47M	29.25M
Total Liabilities	145.45M	145.60M	145.81M	138.46M	95.63M	82.86M
Stockholders Equity	79.12M	116.06M	152.61M	142.01M	239.62M	295.88M
Cash Flow
Free Cash Flow	-72.40M	-72.08M	-79.97M	-90.58M	-150.03M	-117.80M
Operating Cash Flow	-69.62M	-68.37M	-78.20M	-86.96M	-143.83M	-111.90M
Investing Cash Flow	134.41M	149.30M	-80.08M	70.72M	-36.61M	-7.79M
Financing Cash Flow	430.00K	960.00K	150.36M	1.66M	122.78M	174.34M

MacroGenics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.58
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGNX, the sentiment is Neutral. The current price of 1.58 is above the 20-day moving average (MA) of 1.40, above the 50-day MA of 1.49, and below the 200-day MA of 2.55, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.69 is Neutral, neither overbought nor oversold. The STOCH value of 90.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MGNX.

MacroGenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRBU	55 Neutral	$162.76M	―	-52.76%	―	-70.31%	-11.68%
Sector *	52 Neutral	$7.53B	0.20	-61.87%	2.28%	16.72%	1.10%
MGNX	49 Neutral	$92.74M	―	-60.25%	―	255.31%	-141.39%
VXRT	47 Neutral	$68.49M	―	-114.74%	―	433.43%	49.04%
PLRX	37 Underperform	$73.05M	―	-63.22%	―	-100.00%	-26.44%
TNYA	36 Underperform	$102.94M	―	-76.21%	―	―	23.55%
ELTX	30 Underperform	$134.69M	―	-744.59%	―	―	27.65%

MacroGenics Corporate Events

MacroGenics Enters Royalty Purchase Agreement with Sagard

On June 9, 2025, MacroGenics, Inc. entered into a Royalty Purchase Agreement with Sagard Healthcare Partners, selling its rights to receive royalties on global net sales of ZYNYZ (retifanlimab-dlwr) starting July 1, 2025. MacroGenics received a $70 million upfront payment, which extends its cash runway through the first half of 2027. Sagard will collect royalties until they reach $140 million, after which MacroGenics will resume collecting royalties. This agreement allows MacroGenics to retain other economic interests in ZYNYZ, including potential development and commercial milestones, while continuing to support global manufacturing needs.

The most recent analyst rating on (MGNX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.

MacroGenics Holds Annual Stockholders Meeting on May 21

On May 21, 2025, MacroGenics, Inc. held its Annual Meeting of Stockholders, where approximately 82% of the company’s common stock was represented. During the meeting, stockholders elected four Class III directors for a three-year term, ratified the appointment of Ernst & Young LLP as the independent auditor for 2025, approved executive compensation, and amended the 2023 Equity Incentive Plan to increase available shares by 1,250,000. These decisions reflect the company’s ongoing governance and strategic planning efforts, potentially impacting its operational focus and shareholder value.

The most recent analyst rating on (MGNX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.